Scott T. Aaronson

469 total citations
17 papers, 256 citations indexed

About

Scott T. Aaronson is a scholar working on Pharmacology, Psychiatry and Mental health and Neurology. According to data from OpenAlex, Scott T. Aaronson has authored 17 papers receiving a total of 256 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pharmacology, 6 papers in Psychiatry and Mental health and 5 papers in Neurology. Recurrent topics in Scott T. Aaronson's work include Treatment of Major Depression (10 papers), Neurological disorders and treatments (4 papers) and Electroconvulsive Therapy Studies (4 papers). Scott T. Aaronson is often cited by papers focused on Treatment of Major Depression (10 papers), Neurological disorders and treatments (4 papers) and Electroconvulsive Therapy Studies (4 papers). Scott T. Aaronson collaborates with scholars based in United States, Singapore and United Kingdom. Scott T. Aaronson's co-authors include Harold A. Sackeïm, Mark Bunker, Charles R. Conway, Mark A. Demitrack, Craig Mallinckrodt, A. John Rush, Michael E. Thase, Teresa A. Pigott, Apurva Prakash and Joan Prudic and has published in prestigious journals such as Biological Psychiatry, Psychological Medicine and Neuropsychopharmacology.

In The Last Decade

Scott T. Aaronson

13 papers receiving 251 citations

Peers

Countries citing papers authored by Scott T. Aaronson

Since Specialization

Citations

This map shows the geographic impact of Scott T. Aaronson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott T. Aaronson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott T. Aaronson more than expected).

Fields of papers citing papers by Scott T. Aaronson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott T. Aaronson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott T. Aaronson. The network helps show where Scott T. Aaronson may publish in the future.

Co-authorship network of co-authors of Scott T. Aaronson

This figure shows the co-authorship network connecting the top 25 collaborators of Scott T. Aaronson. A scholar is included among the top collaborators of Scott T. Aaronson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott T. Aaronson. Scott T. Aaronson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – 12-month data from an open-label pilot study 2025 ·Journal of Affective Disorders ·(unknown), (unknown), (unknown), (unknown), Katherine Eisen, Melanie Lean, (unknown), Michael J. Ostacher, Scott T. Aaronson, Trisha Suppes	0
2	Characterizing the effects of vagus nerve stimulation on symptom improvement in markedly treatment-resistant major depressive disorder: A RECOVER trial report 2025 ·Journal of Affective Disorders ·Harold A. Sackeïm, Charles R. Conway, Scott T. Aaronson, Mark Bunker, Charles M. Gordon, Ying-Chieh Lee, (unknown), (unknown), (unknown), A. John Rush	0
3	Comparison of the Patient Health Questionnaire-9 and Quick Inventory of Depressive Symptomatology-Self Report in assessing the antidepressant effects of Transcranial Magnetic Stimulation: Sensitivity to change 2024 ·Kenneth Pages, Scott T. Aaronson, Linda L. Carpenter, Todd M. Hutton, A. John Rush, Harold A. Sackeïm	4
4	Update on the assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form-2 (ATHF-SF2) 2024 ·Journal of Psychiatric Research ·Harold A. Sackeïm, Scott T. Aaronson, Mark Bunker, Charles R. Conway, Mark S. George, (unknown), Joan Prudic, Michael E. Thase, Allan H. Young, A. John Rush	4
5	Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study 2023 ·Neuropsychopharmacology ·Sagar V. Parikh, Scott T. Aaronson, Sanjay J. Mathew, Gustavo Alva, Charles DeBattista, Stephen Kanes, Robert Lasser, Amy Bullock, (unknown), JungAh Jung, Fiona Forrestal, (unknown), (unknown), (unknown), James Doherty	15
6	Alternative metrics for characterizing longer-term clinical outcomes in difficult-to-treat depression: II. Sensitivity to treatment effects 2023 ·Australian & New Zealand Journal of Psychiatry ·Scott T. Aaronson, Harold A. Sackeïm, (unknown), (unknown), Teresa Greco, Mark Bunker, Charles R. Conway, Koen Demyttenaere, Allan H. Young, R. Hamish McAllister‐Williams, A. John Rush	5
7	Alternative metrics for characterizing longer-term clinical outcomes in difficult-to-treat depression: I. Association with change in quality of life 2023 ·Psychological Medicine ·Harold A. Sackeïm, A. John Rush, Teresa Greco, (unknown), (unknown), Mark Bunker, Scott T. Aaronson, (unknown), Koen Demyttenaere, Allan H. Young, R. Hamish McAllister‐Williams	4
8	Long-Term Safety and Efficacy of Initial and Repeat Treatment Courses With Zuranolone in Adult Patients With Major Depressive Disorder 2023 ·The Journal of Clinical Psychiatry ·Andrew J. Cutler, Gregory W. Mattingly, Susan G. Kornstein, Scott T. Aaronson, Robert Lasser, Hongling Zhang, (unknown), (unknown), (unknown), Catherine Miller, (unknown), Fiona Forrestal, James Doherty	8
9	Zuranolone in Major Depressive Disorder: Interim Safety Results From a Phase 3, Open-Label, Longitudinal Study 2021 ·Biological Psychiatry ·Andrew J. Cutler, Scott T. Aaronson, Gregory W. Mattingly, Samuel T. Wilkinson, Robert Lasser, Indrani Nandy, Brian Werneburg, Jeffrey M. Jonas, Stephen Kanes, Timothy Y. Mariano	1
10	P.0672 Zuranolone 30 mg in major depressive disorder: results through 1-year follow-up from the Phase 3, open-label, SHORELINE study 2021 ·European Neuropsychopharmacology ·Andrew J. Cutler, Scott T. Aaronson, Gregory W. Mattingly, Samuel T. Wilkinson, Robert Lasser, Indrani Nandy, Brian Werneburg, (unknown), (unknown)	2
11	Research challenges in chronic diseases: Difficult to treat depression 2021 ·Brain stimulation ·A. John Rush, Harold A. Sackeïm, (unknown), Mark Bunker, Steven D. Hollon, Koen Demyttenaere, Allan H. Young, Scott T. Aaronson, Maxine Dibué, Michael E. Thase	0
12	Treatment-Resistant Depression in Adolescents: Clinical Features and Measurement of Treatment Resistance 2020 ·Journal of Child and Adolescent Psychopharmacology ·Jeffrey R. Strawn, Scott T. Aaronson, (unknown), G. Randolph Schrodt, Richard C. Holbert, Sarah Verdoliva, Karen Heart, Mark A. Demitrack, Paul E. Croarkin	13
13	The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF) 2019 ·Journal of Psychiatric Research ·Harold A. Sackeïm, Scott T. Aaronson, Mark Bunker, Charles R. Conway, Mark A. Demitrack, Mark S. George, Joan Prudic, Michael E. Thase, A. John Rush	69
14	The Assessment and Management of Treatment Resistant Depression in the Elderly 2018 ·American Journal of Geriatric Psychiatry ·William M. McDonald, Georgios Petrides, Scott T. Aaronson, (unknown)	0
15	Olanzapine Versus Divalproex Versus Placebo in the Treatment of Mild to Moderate Mania 2008 ·The Journal of Clinical Psychiatry ·Mauricio Tohen, Eduard Vieta, Guy M. Goodwin, Bin Sun, Jay D. Amsterdam, Michael Banov, Anantha Shekhar, Scott T. Aaronson, L. M. Bardenstein, (unknown), В А Точилов, Dan Prelipceanu, Heather S. Oliff, Ludmila Kryzhanovskaya, Charles L. Bowden	66
16	Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder 2007 ·Current Medical Research and Opinion ·Teresa A. Pigott, Apurva Prakash, Lesley M. Arnold, Scott T. Aaronson, Craig Mallinckrodt, Madelaine M. Wohlreich	47
17	Selective impairment of nutrient absorption from intestines with chronic venous hypertension. 1986 ·PubMed ·I. James Sarfeh, Scott T. Aaronson, (unknown), Eric B. Rypins, G. Robert Mason, (unknown), Daniel Hollander	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact